[Allogeneic stem cell transplantation].
Over the last two decades, four major therapeutic approaches have dramatically changed the prognosis in chronic myelogenous leukemia(CML). Those include allogeneic stem cell transplantation, interferon-alpha based regimen, donor-leukocyte infusions, and the revolutionary BCR/ABL tyrosine kinase inhibitor such as STI571. Each modality has exploited and targeted different aspects of CML biology, and is associated with different risk-benefit ratios. In this section, we update the results of both related and unrelated donor transplantation, donor lymphocyte infusions, and non-myeloablative stem cell transplantation in CML in comparison with the other treatment modalities.
Sawafuji
K
K
Division of Hematology, Department of Internal Medicine, Keio University School of Medicine.
Okamoto
S
S
D000328:Adult; D000368:Aged; D018380:Hematopoietic Stem Cell Transplantation / Q000401:mortality; D006650:Histocompatibility Testing; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000401:mortality / Q000628:therapy*; D017710:Lymphocyte Transfusion / Q000401:mortality; D008875:Middle Aged; D015996:Survival Rate; D014019:Tissue Donors; D014184:Transplantation, Homologous
D007372:Interferons